The P-ERK1/2 levels were comparable to those seen in human melanoma cell lines with oncogenic BRAF or NRAS mutations, in contrast to a cell line with wild-type BRAF and NRAS (Figure 1C, D; Table 1). This evidence concerns the gene MAPK3 and melanoma.